Q4 2024 Earnings Call Transcript February 18, 2025 Axsome Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

Harmony Biosciences' ( NASDAQ: HRMY) stock fell about 7.3% after U.S. FDA notified the company that it will not review the ...

Harmony Biosciences currently markets pitolisant as WAKIX® in the U.S. for the treatment of EDS or cataplexy in adult patients with narcolepsy and for EDS in pediatric patients 6 years of age and ...

Avadel Pharmaceuticals plc (NASDAQ:AVDL – Get Free Report) was the target of a large decrease in short interest in January. As of January 31st, there was short interest totalling 10,550,000 shares, a ...

Nations Financial Group Inc. IA ADV acquired a new position in Avadel Pharmaceuticals plc (NASDAQ:AVDL – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & ...

Q4 2024 Management View CEO Herriot Tabuteau highlighted that Axsome has expanded its CNS portfolio to include three commercial products and three late-stage pipeline candidates. The company aims to ...

AXSM's fourth-quarter 2024 earnings miss estimates while revenues beat the same. Net product sales rise year over year.

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.